138 related articles for article (PubMed ID: 7650235)
1. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate.
Srinivas NR; Shyu WC; Upmalis D; Lee JS; Barbhaiya RH
J Clin Pharmacol; 1995 Apr; 35(4):432-7. PubMed ID: 7650235
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction between butorphanol nasal spray and oral metoclopramide in healthy women.
Vachharajani NN; Shyu WC; Barbhaiya RH
J Clin Pharmacol; 1997 Oct; 37(10):979-85. PubMed ID: 9505990
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration.
Vachharajani NN; Shyu WC; Nichola PS; Boulton DW
Cephalalgia; 2002 May; 22(4):282-7. PubMed ID: 12100090
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
[TBL] [Abstract][Full Text] [Related]
5. Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine.
Shyu WC; Barbhaiya RH
Br J Clin Pharmacol; 1996 Oct; 42(4):513-7. PubMed ID: 8904627
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
[TBL] [Abstract][Full Text] [Related]
7. Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder.
Obaidi M; Offman E; Messina J; Carothers J; Djupesland PG; Mahmoud RA
Headache; 2013 Sep; 53(8):1323-33. PubMed ID: 23992438
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
Berges A; Walls C; Lener SE; McDonald SA
Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969
[TBL] [Abstract][Full Text] [Related]
9. Zelrix: a novel transdermal formulation of sumatriptan.
Pierce M; Marbury T; O'Neill C; Siegel S; Du W; Sebree T
Headache; 2009 Jun; 49(6):817-25. PubMed ID: 19438727
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of sumatriptan nasal spray in adolescents.
Christensen ML; Mottern RK; Jabbour JT; Fuseau E
J Clin Pharmacol; 2003 Jul; 43(7):721-6. PubMed ID: 12856385
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer.
Davis GA; Rudy AC; Archer SM; Wermeling DP
Am J Health Syst Pharm; 2004 Feb; 61(3):261-6. PubMed ID: 14986556
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of sumatriptan nasal spray in children.
Christensen ML; Mottern RK; Jabbour JT; Fuseau E
J Clin Pharmacol; 2004 Apr; 44(4):359-67. PubMed ID: 15051742
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02.
Pal A; Gautam A; Munjal S
J Clin Pharmacol; 2017 Nov; 57(11):1472-1478. PubMed ID: 28597922
[TBL] [Abstract][Full Text] [Related]
14. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of butorphanol nasal spray in patients with renal impairment.
Shyu WC; Morgenthien EA; Barbhaiya RH
Br J Clin Pharmacol; 1996 May; 41(5):397-402. PubMed ID: 8735680
[TBL] [Abstract][Full Text] [Related]
16. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine.
Touchon J; Bertin L; Pilgrim AJ; Ashford E; Bès A
Neurology; 1996 Aug; 47(2):361-5. PubMed ID: 8757005
[TBL] [Abstract][Full Text] [Related]
17. Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study.
Wermeling DP; Grant GM; Lee A; Alexander N; Rudy AC
Clin Ther; 2005 Apr; 27(4):430-40. PubMed ID: 15922816
[TBL] [Abstract][Full Text] [Related]
18. Multiple-dose phase I study of transnasal butorphanol.
Shyu WC; Pittman KA; Robinson D; Barbhaiya RH
Clin Pharmacol Ther; 1993 Jul; 54(1):34-41. PubMed ID: 8330463
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers.
Moore KH; Leese PT; McNeal S; Gray P; O'Quinn S; Bye C; Sale M
Clin Ther; 2002 Apr; 24(4):583-94. PubMed ID: 12017403
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability of intranasal butorphanol administered from a single-dose sprayer.
Davis GA; Rudy AIa; Archer SM; Wermeling DP
Am J Health Syst Pharm; 2005 Jan; 62(1):48-53. PubMed ID: 15658072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
